1. Home
  2. BIVI vs PMI Comparison

BIVI vs PMI Comparison

Compare BIVI & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$2.18

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

PMI

Picard Medical Inc.

HOLD

Current Price

$0.15

Market Cap

14.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIVI
PMI
Founded
2013
1981
Country
United States
United States
Employees
N/A
75
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
14.1M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
BIVI
PMI
Price
$2.18
$0.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
177.7K
6.3M
Earning Date
05-11-2026
06-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.06
$0.11
52 Week High
$9.09
$13.68

Technical Indicators

Market Signals
Indicator
BIVI
PMI
Relative Strength Index (RSI) 64.39 37.92
Support Level $1.22 $0.15
Resistance Level N/A $0.27
Average True Range (ATR) 0.22 0.02
MACD 0.02 0.01
Stochastic Oscillator 80.36 18.51

Price Performance

Historical Comparison
BIVI
PMI

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

About PMI Picard Medical Inc.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.

Share on Social Networks: